SCHEMBL7603897

SCHEMBL7603897

CC(C)(C)N(C(=O)O)S(=O)(=O)CCc1cccc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
MTNR1A P48039 2/20 0.44
KDM4E B2RXH2 1/20 0.41
CDYL Q9Y232 1/20 0.41
MCL1 Q07820 3/20 0.40
CYP1A2 P05177 2/20 0.40
GRM2 Q14416 1/20 0.40
GRM3 Q14832 1/20 0.40
CTNNB1 P35222 1/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 1/20 0.40
NR1I2 O75469 1/20 0.39
LMNA P02545 1/20 0.39
ADRA2A P08913 1/20 0.39
ACHE P22303 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6158774 0.78 KMT2A (0.50)
SCHEMBL13900920 0.75 NQO2 (0.54) NQO2TDP1MTNR1ACYP1A2CYP2D6
SCHEMBL14675837 0.75 NQO2 (0.48) NQO2TDP1MTNR1AMCL1GRM2
SCHEMBL23649245 0.74 TDP1 (0.46) TDP1MTNR1AKDM4ECDYLMCL1
SCHEMBL5610092 0.74 NQO2 (0.53) NQO2TDP1MTNR1ACDYLMCL1
SCHEMBL7382528 0.74 KEAP1 (0.54) TDP1KDM4EHTR2A
SCHEMBL5609972 0.73 NQO2 (0.63) NQO2TDP1MTNR1ACYP1A2CYP2D6
SCHEMBL31078221 0.73 NQO2 (0.54) NQO2TDP1MTNR1AKDM4EMCL1
SCHEMBL497025 0.73 NQO2 (0.54) NQO2TDP1MTNR1AKDM4EMCL1
SCHEMBL7601922 0.73 KMT2A (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946502-B1 SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS WARNER LAMBERT CO (US) 2002-12-18 EP disclosed
US-20020156094-A1 Sulfonamide interleukin-1beta converting enzyme inhibitors WARNER-LAMBERT COMPANY 2002-10-24 US disclosed
US-6316415-B1 INHIBITORS OF INTERLEUKIN-1.BETA. CONVERTING ENZYME THAT HAVE THE TREATMENT OF STROKE, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS, INFLAMMATORY DISEASES, SEPTIC SHOCK AND TO AN INHIBITOR OF INTERLEUKIN-1.BETA. CONVERTING ENZYME. BASF AKTIENGESELLSCHAFT (DE) 2001-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156094-A1 Sulfonamide interleukin-1beta converting enzyme inhibitors IL1A, IL1B, IL1R1 NQO2 487/4885TDP1 1601/4885MTNR1A 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.